Estrogen Clinical Trials

44 recruitingLast updated: June 19, 2026

There are 44 actively recruiting estrogen clinical trials across 40 countries. Studies span Phase 2, Phase 4, Not Applicable, Phase 3, Phase 1. Top locations include Houston, Texas, United States, Boston, Massachusetts, United States, Chicago, Illinois, United States. Updated daily from ClinicalTrials.gov.


Estrogen Trials at a Glance

44 actively recruiting trials for estrogen are listed on ClinicalTrialsFinder across 6 cities in 40 countries. The largest study group is Phase 2 with 17 trials, with the heaviest enrollment activity in Houston, Boston, and Chicago. Lead sponsors running estrogen studies include Mayo Clinic, Aarhus University Hospital, and City of Hope Medical Center.

Browse estrogen trials by phase

Treatments under study

About Estrogen Clinical Trials

Looking for clinical trials for Estrogen? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Estrogen trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Estrogen clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 44 trials

Recruiting
Phase 3

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

Estrogen Receptor-Positive Breast CarcinomaHER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8+2 more
National Cancer Institute (NCI)1,978 enrolled22 locationsNCT07391774
Recruiting
Phase 2

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

Breast CarcinomaEstrogen Receptor-Positive Breast CarcinomaBreast Ductal Carcinoma in Situ+3 more
National Cancer Institute (NCI)200 enrolled11 locationsNCT06184750
Recruiting
Phase 2

Reishi Mushroom Extract for Fatigue and/or Arthralgias/Myalgias in Patients With Breast Cancer on Aromatase Inhibitors

Estrogen Receptor-Positive Breast Carcinoma
Mayo Clinic80 enrolled23 locationsNCT06028022
Recruiting
Phase 2

PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

Breast CancerMetastatic Breast CancerBreast Neoplasms+6 more
Kristina A. Fanucci297 enrolled1 locationNCT07222215
Recruiting
Phase 3

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Hoffmann-La Roche1,050 enrolled352 locationsNCT06065748
Recruiting
Phase 2

Ph 2 Elacestrant in ER Positive Uterine Sarcomas

Estrogen Receptor Positive TumorEndometrial Stromal SarcomaUterine Sarcoma+6 more
Dana-Farber Cancer Institute30 enrolled1 locationNCT07467772
Recruiting
Phase 2

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

Breast CancerTriple-Negative Breast CancerMetastatic Breast Cancer+2 more
UNC Lineberger Comprehensive Cancer Center700 enrolled2 locationsNCT07340541
Recruiting

Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy

Estrogen Receptor-Positive Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+4 more
Mayo Clinic35 enrolled1 locationNCT06401889
Recruiting
Phase 2

Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer

Metastatic Breast CancerAnatomic Stage IV Breast Cancer AJCC v8Estrogen Receptor-positive Breast Cancer+1 more
Mayo Clinic35 enrolled1 locationNCT06525766
Recruiting

ATENEA Study: Adherence to Creatine-Based Nutritional Supplementation in Estrogen-Depleted Women

MenopauseEstrogen Deficiency
Margan Biotech100 enrolled4 locationsNCT07580846
Recruiting
Phase 2

SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers

Triple-Negative Breast CancerMetastatic Breast CancerEstrogen-receptor-low Breast Cancer
Kathy Miller168 enrolled6 locationsNCT05846789
Recruiting
Phase 4

Disentangling the Effects of Daily Stress, Sleep, and Sex Hormones on Accelerated Vascular Aging in Midlife Women

EstrogenPremenopause
University of Delaware30 enrolled1 locationNCT06745466
Recruiting
Phase 2

High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer

Estrogen Receptor-Positive Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage 0 Breast Cancer AJCC v8+5 more
City of Hope Medical Center36 enrolled1 locationNCT06538389
Recruiting
Not Applicable

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Breast NeoplasmsCarcinoma, Ductal, BreastReceptors, Estrogen (for ER-positive Requirement)
Natera, Inc.725 enrolled39 locationsNCT07214532
Recruiting
Not Applicable

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8Prognostic Stage IV Breast Cancer AJCC v8HER2/Neu Negative+3 more
SWOG Cancer Research Network739 enrolled723 locationsNCT03723928
Recruiting
Phase 2

Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery

Estrogen Receptor-Positive Breast CarcinomaHER2-Negative Breast Carcinoma
Mayo Clinic40 enrolled1 locationNCT06450873
Recruiting
Not Applicable

Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

Triple-Negative Breast CarcinomaHER2-Positive Breast CarcinomaInvasive Breast Carcinoma+9 more
M.D. Anderson Cancer Center120 enrolled8 locationsNCT02945579
Recruiting

GLP-1RA Effects on Lean Mass and Bone Health in Midlife Women

Body CompositionMuscle FunctionGLP - 1+1 more
University of Kansas Medical Center50 enrolled1 locationNCT07422987
Recruiting
Phase 3

Estradiol and Testosterone Subdermal Implants for Menopause Treatment (ESTIME)

MenopauseTestosterone DeficiencyEstrogen Deficiency
University of Sao Paulo General Hospital140 enrolled1 locationNCT06343870
Recruiting

Active Surveillance in Older Women With ER+ Breast Cancer

Early Stage Estrogen Receptor (ER) Positive Breast Cancer
University of Pittsburgh50 enrolled1 locationNCT07262138